Pharma Stocks Outlook for the week – 07 to 11.09.2015
( www.rupeedesk.in )
Stocks
of frontline pharmaceutical companies are seen trading based on specific
triggers, with Cipla particularly being in focus due to its US acquisitions
announced yesterday. There is no sectoral trigger next week in the pharma
space, some positivity is seen though with pharma being defensive sector, but
mostly it would be stock-specific.
Cipla
Ltd yesterday announced the acquisition of two US-based companies InvaGen Pharmaceuticals
Inc, and Exelan Pharmaceuticals Inc for a combined value of $550 mln in an
allcash deal. The move is seen to be a positive one by the Street. The
acquisitions will strengthen the overall presence of Cipla in the US in terms
of scale, revenue, and manufacturing opportunities, and would enable widening
of Cipla's product portfolio.
